Abstract B075: The role of TET1 and hydroxymethylation in high-risk prostate cancer

The Ten-eleven translocation (TET) proteins are dioxygenases that catalyze the oxidation of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) as part of the DNA demethylation pathway. Gene silencing through cytosine methylation contributes to cancer formation, but how hydroxymethylation affec...

Full description

Saved in:
Bibliographic Details
Published inCancer research (Chicago, Ill.) Vol. 78; no. 16_Supplement; p. B075
Main Authors Smeets, Elien, Spans, Lien, Prekovic, Stefan, Broeck, Thomas Van den, Moris, Lisa, Gevaert, Thomas, Helsen, Christine, Joniau, Steven, Claessens, Frank
Format Journal Article
LanguageEnglish
Published 15.08.2018
Online AccessGet full text

Cover

Loading…
Abstract The Ten-eleven translocation (TET) proteins are dioxygenases that catalyze the oxidation of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) as part of the DNA demethylation pathway. Gene silencing through cytosine methylation contributes to cancer formation, but how hydroxymethylation affects gene expression is largely unknown. In this work, TET1 and genomic hydroxymethylation were investigated in a high-risk prostate cancer cohort for which exome sequencing data are available (1). Immunohistochemical analysis of tumor versus nontumor prostate biopsies from high-risk prostate cancer showed a strong reduction of genome-wide 5hmC and milder but still significant reduction of 5mC levels in prostate cancer tissue compared to control tissue. Copy number analysis of high-risk prostate cancer showed a loss of the TET1 genomic region in 6 out of 39 samples of our cohort. As expected, the mRNA levels of TET1 were decreased in these tumor samples. Recently, an alternative promoter of TET1 was discovered. This promoter generates a novel isoform lacking the CXXC-domain, which is called TET1ALT (2). We therefore performed functional analyses of the two TET1 promoters in prostate cancer cells. Interestingly, the promoter controlling expression of the endogenous full-length TET1 is less active in prostate cancer cell line PC-3, while the alternative promoter generating TET1ALT is more active in these cells. This is shown by luciferase constructs driven by the two promoter regions. In conclusion, our findings indicate that there is a drop in (hydroxy)methylation levels in high-risk prostate cancer that correlates with decreased TET1 expression levels and in some cases by a copy number loss of TET1. We are currently working on a more detailed analysis of TET1 promoter usage and control. This will unravel the regulation of hydroxymethylation in prostate cancer, which is crucial for the understanding of prostate cancer development and progression. References: 1. Spans L, Van den Broeck T, Smeets E, et al. Genomic and epigenomic analysis of high-risk prostate cancer reveals changes in hydroxymethylation and TET1. Oncotarget 2016;7(17):24326-38. 2. Good CR, Madzo J, Patel B, et al. A novel isoform of TET1 that lacks a CXXC domain is overexpressed in cancer. Nucleic Acids Res 2017;45(14):8269-81. Citation Format: Elien Smeets, Lien Spans, Stefan Prekovic, Thomas Van den Broeck, Lisa Moris, Thomas Gevaert, Christine Helsen, Steven Joniau, Frank Claessens. The role of TET1 and hydroxymethylation in high-risk prostate cancer [abstract]. In: Proceedings of the AACR Special Conference: Prostate Cancer: Advances in Basic, Translational, and Clinical Research; 2017 Dec 2-5; Orlando, Florida. Philadelphia (PA): AACR; Cancer Res 2018;78(16 Suppl):Abstract nr B075.
AbstractList The Ten-eleven translocation (TET) proteins are dioxygenases that catalyze the oxidation of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) as part of the DNA demethylation pathway. Gene silencing through cytosine methylation contributes to cancer formation, but how hydroxymethylation affects gene expression is largely unknown. In this work, TET1 and genomic hydroxymethylation were investigated in a high-risk prostate cancer cohort for which exome sequencing data are available (1). Immunohistochemical analysis of tumor versus nontumor prostate biopsies from high-risk prostate cancer showed a strong reduction of genome-wide 5hmC and milder but still significant reduction of 5mC levels in prostate cancer tissue compared to control tissue. Copy number analysis of high-risk prostate cancer showed a loss of the TET1 genomic region in 6 out of 39 samples of our cohort. As expected, the mRNA levels of TET1 were decreased in these tumor samples. Recently, an alternative promoter of TET1 was discovered. This promoter generates a novel isoform lacking the CXXC-domain, which is called TET1ALT (2). We therefore performed functional analyses of the two TET1 promoters in prostate cancer cells. Interestingly, the promoter controlling expression of the endogenous full-length TET1 is less active in prostate cancer cell line PC-3, while the alternative promoter generating TET1ALT is more active in these cells. This is shown by luciferase constructs driven by the two promoter regions. In conclusion, our findings indicate that there is a drop in (hydroxy)methylation levels in high-risk prostate cancer that correlates with decreased TET1 expression levels and in some cases by a copy number loss of TET1. We are currently working on a more detailed analysis of TET1 promoter usage and control. This will unravel the regulation of hydroxymethylation in prostate cancer, which is crucial for the understanding of prostate cancer development and progression. References: 1. Spans L, Van den Broeck T, Smeets E, et al. Genomic and epigenomic analysis of high-risk prostate cancer reveals changes in hydroxymethylation and TET1. Oncotarget 2016;7(17):24326-38. 2. Good CR, Madzo J, Patel B, et al. A novel isoform of TET1 that lacks a CXXC domain is overexpressed in cancer. Nucleic Acids Res 2017;45(14):8269-81. Citation Format: Elien Smeets, Lien Spans, Stefan Prekovic, Thomas Van den Broeck, Lisa Moris, Thomas Gevaert, Christine Helsen, Steven Joniau, Frank Claessens. The role of TET1 and hydroxymethylation in high-risk prostate cancer [abstract]. In: Proceedings of the AACR Special Conference: Prostate Cancer: Advances in Basic, Translational, and Clinical Research; 2017 Dec 2-5; Orlando, Florida. Philadelphia (PA): AACR; Cancer Res 2018;78(16 Suppl):Abstract nr B075.
Author Smeets, Elien
Broeck, Thomas Van den
Moris, Lisa
Gevaert, Thomas
Claessens, Frank
Helsen, Christine
Prekovic, Stefan
Joniau, Steven
Spans, Lien
Author_xml – sequence: 1
  givenname: Elien
  surname: Smeets
  fullname: Smeets, Elien
– sequence: 2
  givenname: Lien
  surname: Spans
  fullname: Spans, Lien
– sequence: 3
  givenname: Stefan
  surname: Prekovic
  fullname: Prekovic, Stefan
– sequence: 4
  givenname: Thomas Van den
  surname: Broeck
  fullname: Broeck, Thomas Van den
– sequence: 5
  givenname: Lisa
  surname: Moris
  fullname: Moris, Lisa
– sequence: 6
  givenname: Thomas
  surname: Gevaert
  fullname: Gevaert, Thomas
– sequence: 7
  givenname: Christine
  surname: Helsen
  fullname: Helsen, Christine
– sequence: 8
  givenname: Steven
  surname: Joniau
  fullname: Joniau, Steven
– sequence: 9
  givenname: Frank
  surname: Claessens
  fullname: Claessens, Frank
BookMark eNo9kMtOwzAQRS1UJNLCN-AfcPEkcWyzC1V5SJVAkL3lOA4JpE5le0H-nkQ8VqOr0czVOWu0cqOzCF0D3QIwcQMsE4TnOdu-vO7KlAInd5SzM5T8b1YooZQKwnKeXqB1CB9zZEBZgt7KOkSvTcTL0S2uOov9OFg8trjaV4C1a3A3NX78mo42dtOgYz863Dvc9e8d8X34xCc_hqijxUY7Y_0lOm_1EOzV79yg6n5f7R7J4fnhaVceiJGcEcMpNHUhaspYyotUUpml0EDBGzlz8VZqZmYcq0VuamG5MAAtFHUqc85EnW0Q_3lr5vrgbatOvj9qPymgalGjFgFqEaD-1KiFMvsGeElXtg
ContentType Journal Article
DBID AAYXX
CITATION
DOI 10.1158/1538-7445.PRCA2017-B075
DatabaseName CrossRef
DatabaseTitle CrossRef
DatabaseTitleList CrossRef
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1538-7445
EndPage B075
ExternalDocumentID 10_1158_1538_7445_PRCA2017_B075
GroupedDBID ---
-ET
18M
29B
2WC
34G
39C
476
53G
5GY
5RE
5VS
6J9
AAYXX
ABOCM
ACGFO
ACIWK
ACPRK
ACSVP
ADBBV
ADCOW
ADNWM
AENEX
AFHIN
AFOSN
AFRAH
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BTFSW
CITATION
CS3
DIK
DU5
EBS
EJD
F5P
FRP
GX1
H13
IH2
KQ8
L7B
LSO
OK1
P0W
P2P
PQQKQ
RCR
RHF
RHI
RNS
SJN
TR2
W2D
W8F
WH7
WOQ
YKV
YZZ
ID FETCH-LOGICAL-c975-c701db68b0552762909321d167d91587f9a5c201ea84cb8e78c11f16b294758b3
ISSN 0008-5472
IngestDate Thu Nov 21 23:17:09 EST 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 16_Supplement
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c975-c701db68b0552762909321d167d91587f9a5c201ea84cb8e78c11f16b294758b3
OpenAccessLink https://lirias.kuleuven.be/bitstream/123456789/676689/2/WES%20TET1%20Onco.docx
ParticipantIDs crossref_primary_10_1158_1538_7445_PRCA2017_B075
PublicationCentury 2000
PublicationDate 2018-08-15
PublicationDateYYYYMMDD 2018-08-15
PublicationDate_xml – month: 08
  year: 2018
  text: 2018-08-15
  day: 15
PublicationDecade 2010
PublicationTitle Cancer research (Chicago, Ill.)
PublicationYear 2018
SSID ssj0005105
Score 2.3162951
Snippet The Ten-eleven translocation (TET) proteins are dioxygenases that catalyze the oxidation of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) as part of...
SourceID crossref
SourceType Aggregation Database
StartPage B075
Title Abstract B075: The role of TET1 and hydroxymethylation in high-risk prostate cancer
Volume 78
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaWIiEuqOUh3vKBW-Ul3thOwm2piiqgqLAB9RbFj6iIkl0t20P5X_y_zsR2ErUgKJdo19LOrjPfzoydbz4T8gJyhIVE2jDV8JwJi83KTiVMW0heRhnODXYjH35QB5_F22N5PJn8GrGWzjZ6an7-tq_kf7wKY-BX7JK9hmd7ozAAr8G_cAUPw_WffDzXuFFhYIkPKTnyJyJfsNwvefdo4OTcIlcFz4o-98w33ORAnWLWEctX2PgBJScSwEwg6w7aBTCyGxSBTrpHvp670cWW09PpaCdh8d25zY_AFRs6zBarUKu_Hw0erd23JQSpQDRrBoy-Xi-dD9Geu7T7pUa-bjvenuAod818g2YfcnMmhT-fZ-qGKJsJryMZw3CWj-Gmqu5U04H-4-Mr3s5Rro5vr-YBib0N_fdMjz7tzWeYkAcDY-XtSxmx5yl2KySZV2ioQkNVNFShoRvkJuov4pEN7z4OIvUyMGfjzAOtEAy9_MMvGhVFo-qm3CZ3wrKEzj3GdsjEtXfJrcNAvLhHFhFqFA29ogA0ikCjy4Yi0CgAjV4FGv3a0h5oNAKNeqDdJ-Wb_XLvgIXzOJgpMslMlnCrVa4TVO1TsyKB2p9brjJbwNyypqilgSm5OhdG5y7L4Z_ecKVnhYBVqU4fkK122bqHhBaprLXMZ5BcU2G1rW3GRQOGRZGmyolHJIn3o1p51ZXqL754fP2PPCG3B8Q-JVub9Zl7BiXmRj_vHHoBFPtxIA
link.rule.ids 314,780,784,27924,27925
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Abstract+B075%3A+The+role+of+TET1+and+hydroxymethylation+in+high-risk+prostate+cancer&rft.jtitle=Cancer+research+%28Chicago%2C+Ill.%29&rft.au=Smeets%2C+Elien&rft.au=Spans%2C+Lien&rft.au=Prekovic%2C+Stefan&rft.au=Broeck%2C+Thomas+Van+den&rft.date=2018-08-15&rft.issn=0008-5472&rft.eissn=1538-7445&rft.volume=78&rft.issue=16_Supplement&rft.spage=B075&rft.epage=B075&rft_id=info:doi/10.1158%2F1538-7445.PRCA2017-B075&rft.externalDBID=n%2Fa&rft.externalDocID=10_1158_1538_7445_PRCA2017_B075
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-5472&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-5472&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-5472&client=summon